key: cord-0700521-f09yk0ev
authors: Padmanabhan, Anand; Kanack, Adam J.; Kaplan, Robert B.; Sangli, Swathi
title: COVID‐19 mRNA‐1273 vaccine induces production of vaccine‐induced immune thrombotic thrombocytopenia antibodies
date: 2022-03-26
journal: Am J Hematol
DOI: 10.1002/ajh.26542
sha: 4266eed85756b623e96148a2fa0d153eb64bcf5c
doc_id: 700521
cord_uid: f09yk0ev

[Image: see text]

Kanack and colleagues make the novel finding that binding of antibodies to un-complexed PF4 can distinguish between these two syndromes. Thus, postmortem, the un-complexed PF4 ELISA was used to further characterize our patient's anti-PF4 antibodies. To avoid confounding antibodies that may have developed after heparin exposure, the preheparin (first) blood sample was initially tested. Figure 1 shows that this sample demonstrated a high OD of 3.3852, consistent with VITT antibodies, and was also found to be platelet-activating in the PF4-dependent P-selectin expression assay (PEA), an assay that uses PF4-treated platelets for the sensitive detection of VITT 4 and HIT antibodies. 5 targets. In addition, a recent case of VITT has been reported after HPV vaccination (recombinant human papillomavirus quadrivalent vaccine), which uses nonadenoviral virus-like particle vaccine technology. 6 Thus, we believe the emerging data on VITT after nonadenoviral vector vaccines highlighted by our case suggests that VITT should remain on the differential diagnosis for thrombotic thrombocytopenic reactions seen after multiple different vaccine types so that an accurate diagnosis can be made and appropriate treatment interventions promptly instituted.

We would like to thank Bandana Singh, PhD, for the performance of the PEA study. This work was supported, in part, by National Institutes of Health grants HL158932 (AP). 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Anand Padmanabhan 1 , Adam J. Kanack 

Treatment of AML relapse after Allo-HCT

Diagnosis and management REFERENCES

Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine

Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States

Laboratory testing for VITT antibodies

Persistence of Ad26.COV2.Sassociated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies

A prospective, blinded study of a PF4-dependent assay for HIT diagnosis

Thrombosis and thrombocytopenia after HPV vaccination